Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Cubs Legend Ryne Sandberg Faces Cancer
Cubs legend Ryne Sandberg announces prostate cancer relapse
After announcing he was cancer-free over the summer, Hall of Fame second baseman Ryne Sandberg says disease is back and has "spread to other organs."
Ryne Sandberg Shares Details on Prostate Cancer Relapse
Former Chicago Cubs player Ryne Sandberg recently took to social media to share a devastating update regarding his health with his fans. The ex-MLB second baseman first shocked the sporting world in January 2024 when he revealed that he was suffering from metastatic prostate cancer.
Cubs legend Ryne Sandberg shares prostate cancer relapse
Baseball Hall of Famer and Chicago Cubs icon Ryne Sandberg announced on Dec. 10 that his prostate cancer has relapsed and spread to other organs. Sandberg shared the update on Instagram, saying he has resumed intensive treatment and remains determined to fight the disease.
Therapeutics, Prostate Cancer
Candel Therapeutics Stock More Than Doubles After Strong Prostate Cancer Trial Results: Retail Goes Wild
Shares of Candel Therapeutics surged more than 100% on Wednesday, reaching seven-month highs, as the clinical-stage biopharmaceutical company announced positive results from a late-stage study of its CAN-2409 viral immunotherapy for prostate cancer.
Candel Therapeutics Shares Soar Premarket on Prostate Cancer Study
Shares of Candel Therapeutics took flight in premarket trading Wednesday after the clinical-stage biopharmaceutical company said a late-stage study of its CAN-2409 product candidate met its key goal in prostate cancer.
Candel Therapeutics’ (CADL) Stock Rockets After Groundbreaking Cancer Trial Results
Candel Therapeutics is a clinical-stage biopharmaceutical company that specializes in developing biological immunotherapies aimed at helping patients fight cancer. The company’s leading product, CAN-2409,
News Medical
3h
Prostate cancer vaccines: Progress, challenges, and future directions
Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...
FierceBiotech
3h
Candel burns bright as phase 3 prostate cancer win sends stock up 200%
A phase 3 prostate cancer trial of Candel’s oncolytic virus has met its primary endpoint, sending the stock up more than 200% ...
EURweb
6h
Montell Jordan Advocates Prostate Cancer Awareness After Personal Battle
Montell Jordan is advocating for prostate cancer awareness and emphasizing the importance of early detection, particularly ...
1d
African men most at risk of prostate cancer—new study flags genetic causes
A breakthrough study has identified the genetic risk factors that contribute to increased prostate cancer in African men. The ...
FierceBiotech
1d
FDA clears AngioDynamics’ NanoKnife pulsed field ablation system for prostate cancer
AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...
Medscape
1d
How Are Patients Managing Intermediate-Risk Prostate Cancer?
Adoption of active surveillance or watchful waiting has been increasing among patients with intermediate-risk prostate cancer ...
Renal & Urology News
1d
Prostate Cancer Salvage Radiation After RP Only Benefits Select Patients
Investigators assessed the oncologic benefit of salvage radiation therapy versus observation for men with biochemical recurrence after radical prostatectomy.
1d
on MSN
The early prostate cancer symptoms that appear when you go to the toilet
Use precise geolocation data and actively scan device characteristics for identification. This is done to store and access ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Related topics
Ryne Sandberg
Chicago Cubs
National Basketball Association
Nanoknife
ESPN
Feedback